Biogen - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Biogen
BIIB
|
NASDAQ
|
United States
865
-305
Rank
$32.85B
Market Cap
$9.67B
-$ 0.16B
-1.63%
Revenue
$1.62B
Earnings
7.6K
+0K
+0.46%
Employees
About
Biogen, Inc. (BIIB)
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
25.08.2025 -
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
25.08.2025 -
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
25.08.2025 -
[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
21.08.2025 -
Biogen Stock: Analyst Estimates & Ratings
21.08.2025